- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01861834
Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage
A Safer Approach to Total Parenteral Nutrition in Pediatric Short Bowel Syndrome Intended to Decrease the Frequency and Severity of Liver Damage
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Medstar Georgetown University Hospital
-
Washington, District of Columbia, United States, 20007
- Medstar Georgetown Transplant Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
The targeted population for enrollment is the cohort of patients with TPN-dependent short bowel syndrome, defined as any pediatric patient who, following abdominal surgery, has a residual small bowel length less than 25% of that predicted for gestational age or requires postoperative TPN for more than 42 days because of gastrointestinal intolerance and who has developed TPN-associated liver disease sufficient to pose a significant risk for progression to liver failure based on the following criteria:
- Total serum bilirubin concentration greater than 3 mg/dL after a total duration of TPN greater than 2 months in the absence of a proven episode of bacteremia within the preceding 3 weeks.
PLUS EITHER:
• Platelet count less than 200,000/μL after a total duration of TPN greater than 2 months in the absence of a proven episode of bacteremia within the preceding 3 weeks.
OR
• Serum albumin concentration less than 3.2 mg/dL after a total duration of TPN greater than 2 months in the absence of a proven episode of bacteremia within the preceding 3 weeks.
Patients with coagulopathy due to parenteral nutrition-associated liver disease (INR > 1.2) will be potential candidates for enrollment, because patients with an elevated INR exceeding 2 have demonstrated resolution of coagulopathy after treatment with Omegaven®. Similarly, patients with hyperlipidemia will be potential candidates for enrollment.
Alternatively, patients currently receiving Omegaven that was initiated at another center because of intestinal failure with liver disease that do not need to meet the lab criteria listed above. The subject may continue Omegaven under this protocol at the discretion of the Principle Investigator.
Exclusion Criteria:
Patients with a history of the following will be excluded from enrollment in this protocol:
- Allergy to fish or egg protein.
- Liver disease proven or suspected to be caused by a process other than TPN-dependent short bowel syndrome, including but not limited to hepatitis C, hepatitis B, cystic fibrosis, biliary atresia, Alagille syndrome, familial intrahepatic cholestasis, and alpha-1-antitrypsin deficiency.
- Refusal of third party providers to reimburse hospital for the cost of Omegaven®.
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IND107300
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cholestasis of Parenteral Nutrition
-
University of South FloridaCompletedCholestasis | Cholestasis of Parenteral NutritionUnited States
-
Indiana UniversityActive, not recruitingComparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical NeonatesCholestasis of Parenteral NutritionUnited States
-
Baylor College of MedicineBoston Children's HospitalCompletedCholestasis | Cholestasis of Parenteral NutritionUnited States
-
Wei LiuRecruitingCholestasis of Parenteral NutritionChina
-
Arthur J De LorimierCompletedParenteral Nutrition Associated CholestasisUnited States
-
Hector HernandezApproved for marketingTotal Parenteral Nutrition-induced CholestasisUnited States
-
Cindy HallerTerminatedCholestasis | Total Parenteral Nutrition-induced CholestasisUnited States
-
Sivan KinbergWithdrawnTotal Parenteral Nutrition-induced CholestasisUnited States
-
Jeffrey RudolphUniversity of PittsburghApproved for marketingTotal Parenteral Nutrition-induced CholestasisUnited States
-
PediatrixCompletedTotal Parenteral Nutrition-induced CholestasisUnited States
Clinical Trials on Omegaven 10%
-
National Taiwan University HospitalUnknownCritical Ill Patients in SICUTaiwan
-
General University Hospital, PragueCharles University, Czech Republic; Ministry of Health, Czech RepublicCompletedParenteral NutritionCzechia
-
Children's Hospital Los AngelesCompleted
-
Humanis Klinikum NiederosterreichCompleted
-
Sir Run Run Shaw HospitalUnknown
-
Children's & Women's Health Centre of British ColumbiaChild and Family Research InstituteUnknownCholestasis | Parenteral Nutrition Associated Liver Disease (PNALD)Canada
-
Midwestern Regional Medical CenterTerminatedCancer | Hepatic InjuryUnited States
-
Jagiellonian UniversityCompletedGastrointestinal SurgeryPoland
-
Radboud University Medical CenterCompleted